Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Assets: 2022-2025

Historic Assets for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $513.8 million.

  • Day One Biopharmaceuticals' Assets fell 14.49% to $513.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513.8 million, marking a year-over-year decrease of 14.49%. This contributed to the annual value of $582.8 million for FY2024, which is 54.98% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Assets is $513.8 million, which was down 1.01% from $519.0 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Assets' 5-year high stood at $600.8 million during Q3 2024, with a 5-year trough of $267.8 million in Q1 2022.
  • Over the past 3 years, Day One Biopharmaceuticals' median Assets value was $450.8 million (recorded in 2023), while the average stood at $458.4 million.
  • Data for Day One Biopharmaceuticals' Assets shows a peak YoY increase of 63.59% (in 2025) and a maximum YoY decrease of 14.49% (in 2025) over the last 5 years.
  • Day One Biopharmaceuticals' Assets (Quarterly) stood at $349.1 million in 2022, then grew by 7.73% to $376.0 million in 2023, then surged by 54.98% to $582.8 million in 2024, then fell by 14.49% to $513.8 million in 2025.
  • Its Assets was $513.8 million in Q3 2025, compared to $519.0 million in Q2 2025 and $534.4 million in Q1 2025.